Arcus Biosciences, Inc.
As of Oct 22, 2026, Arcus Biosciences is in Stage 3, the topping phase, now in week 5 (since Sep 22, 2026). It closed at $19.36, 38.7% below its 52-week high and below its 200-day average, which is rising.
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is RCUS early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
RCUS among Biotechnology163rd of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …163 | RCUS | Stage 3 · wk 5 | 60 | −26.6% |
Arcus Biosciences: quick answers
What stage is Arcus Biosciences in?
As of Oct 22, 2026, Arcus Biosciences (RCUS) is in Stage 3, the topping phase. It entered Stage 3 on Sep 22, 2026 and is in week 5. What the four stages mean
Is Arcus Biosciences in an uptrend?
Its uptrend has stalled. Arcus Biosciences is in Stage 3, the topping phase that follows an advance. It trades 21.9% below its 200-day average, which is rising.
How far is Arcus Biosciences from its 52-week high?
Arcus Biosciences closed at $19.36 on Oct 22, 2026, 38.7% below its 52-week high of $31.57. Its 52-week low is $16.78.
How has Arcus Biosciences performed over the past year?
As of Oct 22, 2026, Arcus Biosciences is up 7.3% over the past year and down 16.9% so far in 2026.
Which sector and industry is Arcus Biosciences in?
Arcus Biosciences is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases; and Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.